Darbepoetin alfa

Parenteral
Anaemia of chronic renal failure

Subcutaneous
Anaemia in chemotherapy patients

Hypersensitivity, uncontrolled hypertension.

Pregnancy and lactation, children. Hypertension; history of seizures; hepatic impairment; sickle cell anaemia; sudden stabing migraine-like pain (warning sign of hypotensive crisis); exclude other causes of anaemia; ischaemic vascular disease; thrombocytosis; epilepsy; malignant disease; increase in heparin dose may be needed; increased risk of thrombosis when used for anaemia before orthopedic surgery; CV disease including recent MI/cerebrovascular accident. Monitor haemoglobin, BP and electrolytes; platelet count for 1st 8 wk.

Hypertension, hypotension, chest pain, fatigue, fever, headache, dizziness, GI effects; myalgia, arthralgia, limb pain; skin reactions; shunt reactions, hyperkalaemia; dyspnea, cough, bronchitis; infection; transient increase in platelet count; influenza-like symptoms; peripheral oedema; Inj site pain.

IV/Parenteral/SC: C

No overdosage symptoms reported so far as it has wide therapeutic margin. In the event of polycythaemia, treatment may be temporarily withheld. Phlebotomy may be performed if clinically indicated.

Antagonism of hypotensive effect and increased risk of hyperkalemia with ACE inhibitors and angiotensin II receptor antagonists. Ethanol.

Description:
Mechanism of Action: Darbepoetin alfa is a biosynthetic form of erythropoietin. It stimulates the division and differentiation of erythroid progenitor cells; reticulocytes are released from the bone marrow and matures into erythrocytes thereby regulating erythropoiesis.
Pharmacokinetics:
Absorption: IM admin: Slow absorption and bioavailability is about 37%.
Excretion: Terminal half-lives: 21 hr (IV admin) and 49 hr (SC admin).

Store at 2-8°C.

Các tác nhân tạo máu